Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study.
<h4>Background</h4>Direct oral anticoagulants (DOACs) have comparable efficacy with low-molecular-weight heparin (LMWH) for the treatment of cancer-associated venous thromboembolism (VTE). Whether there is a mortality benefit of DOACs compared with warfarin in the management of VTE in ca...
Main Authors: | Adeel M Khan, Thita Chiasakul, Robert Redd, Rushad Patell, Ellen P McCarthy, Donna Neuberg, Jeffrey I Zwicker |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2022-05-01
|
Series: | PLoS Medicine |
Online Access: | https://doi.org/10.1371/journal.pmed.1004012 |
Similar Items
-
Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017
by: Pamela L. Lutsey, et al.
Published: (2019-10-01) -
Anticoagulation after intracranial hemorrhage in brain tumors: Risk of recurrent hemorrhage and venous thromboembolism
by: Brian J. Carney, et al.
Published: (2020-07-01) -
Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among patients with recurrent venous thromboembolism
by: Hye‐Rim Kang, et al.
Published: (2023-06-01) -
Newer oral anticoagulants in venous thromboembolism
by: Sunil Modi, et al.
Published: (2021-01-01) -
Direct oral anticoagulants and venous thromboembolism
by: Massimo Franchini, et al.
Published: (2016-09-01)